Skip to main
LRMR

LRMR Stock Forecast & Price Target

LRMR Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 71%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Larimar Therapeutics is expected to have enough financial resources to support operations until at least the second quarter of 2027, with the potential launch of their drug nomlabofusp in mid-2027 being a key driver of future stock growth. However, the company may need additional funding sources in order to fully support the drug launch and maximize its potential. The upcoming regulatory updates for nomlabofusp are also seen as a major driver for the company's stock in the near future.

Bears say

Larimar Therapeutics is at a high risk for failure with its single product development focus and potential delays or termination of development campaigns without adequate financing. Additionally, regulatory requirements and the need for additional studies could limit the company's ability to gain market traction and generate revenue. Investors should approach this stock with caution and thoroughly evaluate the company's financial stability and ability to bring its product to market before making any investment decisions.

LRMR has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 71% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Larimar Therapeutics Inc (LRMR) Forecast

Analysts have given LRMR a Buy based on their latest research and market trends.

According to 7 analysts, LRMR has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Larimar Therapeutics Inc (LRMR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.